Observation on the Effect of Bevacizumab Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer
Objective To explore the clinical effect of bevacizumab combined with chemotherapy in patients with advanced gastric cancer.Methods 70 patients with advanced gastric cancer admitted to our hospital from August 2021 to August 2023 were selected as the study objects,and were divided into a study group and a control group by random number table method,with 35 cases in each group.The control group was treated with chemotherapy,and the study group was treated with bevacizumab combined with chemotherapy.Objective response rate,disease control rate,progression-free survival time,overall survival time,serum tumor marker level,quality of life score and incidence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate of the study group were 74.29%and 91.43%,both higher than 51.43%and 68.57%in the control group,with statistical significance(P＜0.05).The progression-free survival time of the study group was(6.85±0.79)months,and the total survival time was(9.64±1.43)months,both of which were longer than(5.08±0.43)months and(7.15±0.72)months of the control group,with statistical significance(P＜0.05).After treatment,the level of serum tumor markers in the study group was lower than that in the control group,and the difference was statistically significant(P＜0.05).After treatment,the Kanofsky Performance score of the study group was higher than that of the control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Bevacizumab combined with chemotherapy has a significant effect in the treatment of advanced gastric cancer patients,which can reduce the level of serum tumor markers,prolong the survival time and improve the quality of life.Moreover,bevacizumab combined treatment does not increase the incidence of adverse reactions,so it is suitable for promotion and application in medical institutions.
NETL
NSTL
万方数据
